A Robust Proof For The Essential Role Of Myd88 In Dcs In Transplant Responses

P. Zhou,C. Li,X. Huang,C. Xue,T. Yang,Y. Li
DOI: https://doi.org/10.1097/00007890-201211271-00841
2012-01-01
Transplantation
Abstract:Introduction: It is well established that toll-like receptors (TLRs) expressed in APCs, especially in dendritic cells (DCs), play important role in many immune responses. All TLR signals except TLR3 depend either entirely or in part on the MyD88 (myeloid differentiation protein 88). However, there is no direct evidence that MyD88 is the trigger and controller for transplantation rejection. In this study, we investigate the essential role of MyD88 in DCs in transplant rejection response by a MyD88 specific inhibitor using a HY-mismatched skin allograft model in mice. Methods: Minor antigen-mismatched (HY-mismatched) skin allograft model (BALB/c ♂ → BALB/c ♀) using MyD88-knockout mice was employed in this study. Wild-type BALB/c immature BMDCs were cocultured with or without ST2825, a novel inhibitor of MyD88, in vitro for 12 hours. DCs treated with or without ST2825 were then transfused into recipients (2×107/mouse) at the time of skin transplantation. Wild-type BALB/c BMDCs were stimulated by TLR agonists in the presence of ST2825 or not for 12 hours in vitro. Costimulatory molecular CD80 were analyzed by flow cytometry and NF-κB activity in nuclei was detected by western blot. Wild-type C57BL/6 T cells stained with CFSE were cocultured with BALB/c DCs for 3 days in the presence of ST2825 or not. CD3+/CFSE+ cells were analyzed by flow cytometry. Results: ST2825 inhibited the upregulation of CD80 and reduced NF-κB activity of DCs upon the stimulation of TLR agonists in vitro. ST2825 dose-dependently inhibited T cell proliferation in mixed lymphocyte culture. The rejection of HY-mismatched skin allografts in MyD88 KO mice could not occur and an immune tolerance was established. The group infused with DCs without ST2825 treatment reversed the tolerance in H-Y mismatched skin transplant in MyD88 KO mice, but the group with DCs treated with ST2825 does not, as shown in Fig 1.Figure: [Rejection depends on the presence of MyD88 in DCs]Conclusion: This study provides profound evidence that the MyD88 in DCs plays important role in transplant alloresponses. MyD88 inhibitor ST2825 leads to effective blocking to TLR signaling in DCs.
What problem does this paper attempt to address?